JF
PTGX icon

Jump Financial’s Protagonist Therapeutics PTGX Stock Holding History

Jump Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,780
Closed -$2.75M – 2079
2025
Q1 		$2.75M Buy
+56,780
New +$2.38M 0.04% 491
2024
Q3 		– Sell
-5,783
Closed -$200K – 2031
2024
Q2 		$200K Buy
+5,783
New +$169K ﹤0.01% 1565
2023
Q4 		– Sell
-35,438
Closed -$591K – 2151
2023
Q3 		$591K Buy
35,438
+21,070
+147% +$409K 0.02% 928
2023
Q2 		$397K Sell
14,368
-53,332
-79% -$1.33M 0.01% 1147
2023
Q1 		$1.56M Buy
+67,700
New +$1.14M 0.06% 436
2022
Q4 		– Sell
-53,190
Closed -$449K – 1948
2022
Q3 		$449K Buy
53,190
+1,926
+4% +$18.2K 0.02% 936
2022
Q2 		$405K Buy
51,264
+16,264
+46% +$197K 0.02% 937
2022
Q1 		$829K Sell
35,000
-2,100
-6% -$59.2K 0.04% 599
2021
Q4 		$1.27M Buy
+37,100
New +$1.17M 0.08% 313

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jump Financial's PTGX Position: Q2 2025 in Review

Jump Financial sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 56,780 shares — an estimated $2.75M sold.

Jump Financial first reported a position in PTGX in Q4 2021 and held it in 9 quarters. The position peaked at $2.75M in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Jump Financial reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jump Financial sold 56,780 Protagonist Therapeutics shares in Q2 2025, an estimated $2.75M.
  • Jump Financial first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 9 quarters.
  • Jump Financial's Protagonist Therapeutics position peaked at $2.75M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Jump Financial's 13F filing for Q2 2025, filed 13 Aug 2025.